Enzyme-catalyzed reactions have begun to transform pharmaceutical manufacturing, offering levels of selectivity and tunability that can dramatically improve chemical synthesis. Combining enzymatic reactions into multistep biocatalytic cascades brings additional benefits.
Design of an in vitro biocatalytic cascade for the manufacture of islatravir Read More »
At the IAS Conference on HIV Science this summer, the results of a phase II, dose-ranging study of islatravir plus doravirine in treatment-naive participants were presented. Four arms were included: three featured differing dosages of islatravir, and the fourth served as a control using doravirine plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF, Truvada). Each arm had roughly
Islatravir Is Potent and Long-Lasting — and May Be Having an Identity Crisis Read More »
Three examples of agents in phase II or III development with less frequent dosing are injectable cabotegravir and rilpivirine (an INSTI + NRTI combination), injectable leronlimab (an anti-CCR5 monoclonal antibody in the same class as ibalizumab), and parenteral or subdermal islatravir (MK-8591, in a new class of nucleoside reverse transcriptase translocation inhibitors [NRTTIs]).
Will Islatravir Add Value to Current ART Options? Read More »
A new antiretroviral named islatravir is showing promise for HIV treatment, and for PrEP delivered through an under-the-skin implant.
Islatravir: A potential PrEP & HIV drug now being tested Read More »
